Dotmatics Announces Investment in BioGlyph for Visualizing, Illustrating, and Modeling Multispecific Antibodies
Dotmatics has made a significant minority investment in BioGlyph, a biotech software startup specializing in proprietary technology to visually illustrate, register, and model multispecific antibodies (MsAbs), aiming to accelerate protein therapeutic development by addressing the growing need for advanced software tools that support complex antibody formats beyond traditional monoclonal antibodies, complementing Dotmatics' new scientific intelligence platform, Luma.
BOSTON, MA - August 6, 2024 – Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, announced a significant minority investment in BioGlyph, a startup biotech software company developing technology to visually illustrate, register, and model biologic molecules, specifically multispecific antibodies (MsAbs).
BioGlyph possesses proprietary technology and exceptional talent in the realm of MsAbs R&D, focused on accelerating and improving the development of protein therapeutics. MsAbs are one of the fastest growing new research modalities, and Dotmatics is supporting customers pursuing new therapies using a multimodal approach to life science discovery.
MsAbs bind two or more antigens, enabling new therapeutic applications that conventional monoclonal antibodies cannot fulfill. This technology is crucial for bridging different cells or receptor proteins on the same cell, presenting groundbreaking opportunities in therapeutic development.
“This investment aligns with the repeated interest we are hearing from customers about the need for software that supports MsAb formats,” said Thomas Swalla, CEO of Dotmatics. “As drug discovery becomes more multidisciplinary, the legacy software in labs isn’t keeping pace with new modalities. That’s why we introduced our new scientific intelligence platform, Luma, which lets scientists connect old and new science in a way that enhances the precision and efficiency of antibody design and production.”
BioGlyph is led by CEO and co-founder Fernando Garces, formerly director of Protein Therapeutics at Gilead Sciences and principal scientist at Amgen, and BioGlyph founder McClain Kressman, a PhD candidate at the University of California, Santa Cruz. Avi Peltz is also a co-founder and leads software development at BioGlyph.
“After 20 years in protein engineering, I recognized that traditional tools couldn't keep up with the increasing complexities of biotherapeutics, especially MsAbs. This led the BioGlyph team to create a visual software solution that empowers protein engineers with creativity while managing registration, data labeling, and in-silico testing of MsAbs' fitness, among other functions,” said Fernando Garces, CEO of BioGlyph. “Our software will empower the R&D scientists to make better decisions that accelerate timelines and lower costs. Working together with Dotmatics will help us bring this in-demand technology to market in an expedited way and one that explores many avenues of integration with Dotmatics’ industry-leading technologies.”
“Dotmatics’ investment in BioGlyph gives us financial resources, leadership, and technical expertise to accelerate the development of our BioGlyph Platform,” said McClain Kressman, founder of BioGlyph. “We are eager to harness the power of AI in life sciences, providing protein engineers with cutting-edge tools for the future.”
About Dotmatics
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists’ favorite applications drive efficiency and accelerate innovation. More than 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 people dedicated to supporting its customers in over 180 countries. Dotmatics has made 14 acquisitions since 2017. The company’s principal office is in Boston, with 14 offices and R&D teams located around the world.
Dotmatics is backed by Insight Partners, a leading global venture capital and private equity firm investing in high-growth technology and software scaleup companies. Learn more about Dotmatics, its platform, and applications including GraphPad Prism, Geneious, SnapGene, Protein Metrics, and LabArchives at https://www.dotmatics.com/.
About BioGlyph
BioGlyph is a biotech firm specializing in Multispecific Antibody research and development. With a focus on innovative therapeutic applications, BioGlyph leverages advanced technologies to design and produce highly specific antibodies that address complex biological challenges.
Media Contacts
Cory Edwards
Vice President, Corporate Communications
Dotmatics
media@dotmatics.com
Jerome Combes-Knoke
Senior Vice President, Strategy & Corporate Development
Dotmatics
corpdev@dotmatics.com
Related
Dotmatics Launches BioGlyph Luma to Accelerate the Future of Protein Design & Engineering
Dotmatics has launched BioGlyph Luma, a next-generation protein design and engineering solution integrated into its Luma Scientific Intelligence Platform, which addresses the Design phase of the protein therapeutics research cycle by enabling real-time traceability, scalable registration, and seamless integration with existing scientific tools to accelerate multimodal biologic R&D workflows with precision and data-driven automation.
A Universal Language for Multispecific Antibodies
The article discusses the challenges of naming structurally diverse multispecific antibodies (MsAbs) and advocates for a building-block-based nomenclature system that captures both component parts and assembly logic, thereby enhancing collaborative research, enabling precise differentiation of complex biologics, and generating structured, AI-ready data to support current workflows and future protein engineering innovations.
The Data Lifecycle: From Instrument Integration to Advanced Analysis
The article discusses how Dotmatics Luma™, a comprehensive scientific data platform, addresses the challenges faced by R&D teams in managing and integrating diverse, multimodal scientific data from instruments and various sources to streamline the entire data lifecycle—from ingestion and processing to advanced analysis—thereby enabling faster, AI-ready insights that accelerate innovation and research outcomes.
New Dotmatics solution to streamline your antibody discovery process
Dotmatics' new Luma Antibody & Protein Engineering solution, built on the AI-native Geneious Luma platform and integrated with tools like GraphPad Prism, streamlines the complex antibody discovery and development process by unifying data, teams, and experimental phases within a single, collaborative environment to enhance biologics R&D productivity and overcome challenges of siloed data and rigid workflows.
Dotmatics Partners with Databricks to Advance Scientific Intelligence in Life Sciences
Dotmatics has partnered with Databricks to enhance scientific intelligence in life sciences by integrating Dotmatics’ Luma™ Scientific Intelligence Platform—supported by products like GraphPad Prism and Geneious—with Databricks’ data intelligence capabilities, enabling life science researchers to unify, analyze, and share large volumes of complex scientific data across various therapeutic discovery modalities such as antibody engineering, CAR-T, and CRISPR, thereby accelerating drug discovery and fostering a new paradigm in biopharmaceutical R&D.
Limitations of Existing Life Science Software—and the Opportunity to Evolve
Existing life science software tools like ELNs, LIMS, and SDMS, while essential for digitizing workflows and managing data, are limited by their siloed, non-real-time, and non-AI-integrated designs, presenting an opportunity to evolve by integrating them into unified, intelligent platforms—such as Dotmatics Luma—that enable connected, workflow-aware, multimodal scientific intelligence with adaptive workflows, real-time data flow, and cross-functional insights without replacing core systems.